VAL — ValiRx Income Statement
0.000.00%
Last trade - 00:00
- £4.57m
- £3.45m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.87 | 2.7 | 1.53 | 1.68 | 2.59 |
Operating Profit | -3.87 | -2.7 | -1.53 | -1.68 | -2.59 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.83 | -2.72 | -1.54 | -1.68 | -2.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.37 | -2.43 | -1.47 | -1.55 | -2.41 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4.3 | -2.39 | -1.44 | -1.52 | -2.37 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.3 | -2.39 | -1.44 | -1.52 | -2.37 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.17 | -0.311 | -0.038 | -0.023 | -0.031 |